NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 1 August 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Dr Craig Buckley Items 1.1 to 4.3.2
4. Dr Andrew Champion Present for all items
5. Dr Patrick De Barr Present for all items
6. Dr Justin Daniels Present for all items
7. Dr Fiona MacPherson Smith Present for all items
8. Professor G.J. Melendez-Torres Present for all items
9. Dr Pratheeban Nambyiah Present for all items
10. Hugo Pedder Present for all items
11. Becky Pennington Present for all items
12. Alan Thomas Present for all items
13. Jaqueline Tomlinson Present for all items
14. Stella O'Brien Present for all items
15. Steve O'Brien Present for all items
16. Britta Stordal Items 1.1 to 4.3.2

NICE staff (key players) present

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Zoe Charles, Heath Technology Assessment Adviser Items 1.1 to 4.3.2

Emily Leckenby, Heath Technology Assessment Analyst Items 1.1 to 4.3.2

Ewa Rupniewska, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Giacomo De Guisa, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.3.2

Adam Storrow, Business Analyst, RIA Present for all items

Marcia Miller, Administrator, TA Items 1 to 4.3.2

Carl Jackson, Assistant Project Manager, COT Present for all items

Portia Dodds, Coordinator, COT Present for all items

External assessment group representatives present

Isaac Mackenzie, BMJ Technology Assessment Group Items 1.1 to 4.1.4

Mariana Bacelar, BMJ Technology Assessment Group Items 1.1 to 4.1.4

Nigel Armstrong, organisation Items 5.1 to xx

Mirre Scholte, organisation Items 5.1 to xx

Clinical, Patient & NHS England experts present

Peter Clark, NHS CDF clinical lead Items 1.1 to 4.3.2

Rachel Downing, Head of Policy & Campaigns, Patient expert nominated by Target Ovarian Cancer Items 1.1 to 4.3.1

Victoria Clare, CEO, Patient expert nominated by Ovarian Cancer Action Charity Items 1.1 to 4.3.1

Anna Hudson, Patient expert nominated by Ovacome Items 1.1 to 4.3.1

Partha Kar, National Specialty Advisor, Diabetes, NHSE, Clinical expert nominated by

Items 5.1 to 5.1.3

Sumaia Mashal, Assistant Director of Medicines Policy Medicines Value & Access, NHSE

Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Radha Todd welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Ana Duarte, Dr David Maudgil, Dominic Pivonka, Min Ven Teo, Dr Peter Baker, Dr Steve Edwards, and Mohamad Farhat.

### News and announcements

* 1. .

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 4 July 2023.

### Appraisal of [olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [Review of TA693] [ID4066]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10978)

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10978).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr James Fotheringham.
     4. The committee discussed confidential information submitted for this item.
  2. Part 2 – Closed session (company representatives, patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10978>.

### Appraisal of [tirzepatide for treating type 2 diabetes [ID3938]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10835)

* 1. Part 1 – Open session
     1. The Vice Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly.
     2. The Vice Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10835)
     3. The Vice Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr James Fotheringham.
  2. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of t Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10835>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 5 September and will start promptly at 9:30am.